Glenmark Pharmaceuticals Ltd Stock Price Today (NSE: GLENMARK)
Fundamental Score
Glenmark Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Glenmark Pharmaceuticals Ltd share price today is ₹2233.90, up +1.99% on NSE/BSE as of 31 July 2026. Glenmark Pharmaceuticals Ltd (GLENMARK) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹64.82K (Cr). The 52-week high for GLENMARK share price is ₹2474.00 and the 52-week low is ₹1792.60. At a P/E ratio of 21.96x, GLENMARK is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 30.49% and a debt-to-equity ratio of 0.06.
Glenmark Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Glenmark Pharmaceuticals Ltd share price chart: 3.33% return over the past month. 52-week high ₹2474.00, 52-week low ₹1792.60.
Glenmark Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2207.20 | ₹2256.70 | ₹2207.00 | ₹2233.90 | 3.71L (Cr) | |
| ₹2270.20 | ₹2270.20 | ₹2182.90 | ₹2190.30 | 4.52L (Cr) | |
| ₹2196.40 | ₹2267.70 | ₹2186.20 | ₹2261.70 | 5.94L (Cr) | |
| ₹2199.90 | ₹2208.00 | ₹2178.20 | ₹2184.60 | 4.90L (Cr) | |
| ₹2218.00 | ₹2220.00 | ₹2183.10 | ₹2196.00 | 5.94L (Cr) | |
| ₹2182.00 | ₹2248.80 | ₹2182.00 | ₹2192.00 | 4.30L (Cr) | |
| ₹2185.10 | ₹2241.30 | ₹2182.80 | ₹2205.10 | 5.68L (Cr) | |
| ₹2245.80 | ₹2249.30 | ₹2221.10 | ₹2242.10 | 2.75L (Cr) | |
| ₹2235.00 | ₹2270.00 | ₹2225.30 | ₹2239.50 | 9.15L (Cr) | |
| ₹2287.90 | ₹2287.90 | ₹2229.00 | ₹2235.50 | 3.56L (Cr) |
Glenmark Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2196.40 | ₹2326.10 | ₹2142.80 | ₹2233.90 | +1.71% | |
| ₹2288.80 | ₹2300.00 | ₹2101.00 | ₹2204.30 | -3.69% | |
| ₹2406.30 | ₹2440.00 | ₹2226.30 | ₹2274.90 | -5.46% | |
| ₹2180.00 | ₹2474.00 | ₹1966.50 | ₹2406.30 | +10.38% | |
| ₹2112.50 | ₹2297.90 | ₹2031.10 | ₹2131.70 | +0.91% | |
| ₹1935.10 | ₹2159.80 | ₹1842.00 | ₹2136.70 | +10.42% | |
| ₹2034.00 | ₹2147.50 | ₹1910.10 | ₹2015.90 | -0.89% | |
| ₹1950.00 | ₹2082.50 | ₹1892.70 | ₹2035.20 | +4.37% | |
| ₹1889.10 | ₹1958.00 | ₹1801.40 | ₹1946.20 | +3.02% | |
| ₹1950.21 | ₹1990.00 | ₹1792.60 | ₹1891.20 | -3.03% | |
| ₹1918.10 | ₹2154.37 | ₹1904.00 | ₹1950.21 | +1.67% | |
| ₹2067.80 | ₹2098.00 | ₹1901.10 | ₹1923.90 | -6.96% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Glenmark Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Glenmark Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLENMARK across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (30.49%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (39.77%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.30%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 21.96 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (51.88%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (15.80%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (25.67% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (21.37x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Institutional Confidence (FII+DII: 39.63%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Negative Free Cash Flow (₹-251.87 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Glenmark Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Glenmark Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Glenmark Pharmaceuticals LtdGlenmark Pharma...Selected✓ GLENMARK • 532296 | 70.7/100 | ₹2233.90₹2234 | ₹64821.57₹64821.57 | 21.96Average 22.0 Average | 30.49%Excellent 30.49% Excellent | 39.77%Excellent 39.77% Excellent | 0.06Excellent 0.1 Excellent | 25.68%Excellent 25.68% Excellent | 9.19%Good 9.19% Good | 0.11% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Glenmark Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for GLENMARK — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹37.11 | ₹2035.20 | 54.8x |
| FY 2023 | ₹10.53 | ₹852.00 | 80.9x |
| FY 2022 | ₹33.37 | ₹424.80 | 12.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Glenmark Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by GLENMARK — dividend yield 0.11%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹70.44 Cr |
| FY 2024 | ₹117.75 Cr |
| FY 2023 | ₹136.61 Cr |
| FY 2022 | ₹92.69 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Glenmark Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for GLENMARK — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
15.80%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
51.88%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.19%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
25.68%
Compounded annual net profit growth over 5 years
Glenmark Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GLENMARK — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Glenmark Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Glenmark Pharmaceuticals Ltd (GLENMARK) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Glenmark Pharmaceuticals Ltd
About GLENMARK (Glenmark Pharmaceuticals Ltd)
Glenmark Pharmaceuticals Ltd is a dynamic global pharmaceutical company driven by innovation and a commitment to improving healthcare outcomes. With a robust presence across both e...merging and developed markets, Glenmark operates at the forefront of pharmaceutical research, development, and manufacturing. The company is actively engaged in pioneering new chemical entities and biosimilars, strategically focusing on therapeutic areas with significant unmet medical needs. Glenmark distinguishes itself through its agile approach to drug development, leveraging cutting-edge technologies and a deep understanding of global healthcare challenges to deliver impactful solutions for patients worldwide. Glenmark's diverse portfolio encompasses a wide range of pharmaceutical products, including specialty medicines, generics, and over-the-counter treatments. This comprehensive offering allows Glenmark to address various healthcare needs across multiple therapeutic areas. The company demonstrates considerable strength in dermatology, respiratory, and oncology, with a growing focus on immunology and other specialized segments. By combining scientific expertise with commercial acumen, Glenmark successfully navigates the complexities of the pharmaceutical industry, ensuring its products reach patients in need while upholding the highest standards of quality and safety. With a global footprint that spans numerous countries, Glenmark Pharmaceuticals maintains a robust infrastructure to support its research, manufacturing, and commercial operations. The company's state-of-the-art manufacturing facilities adhere to stringent international regulatory standards, ensuring the consistent quality and reliability of its products. Glenmark actively fosters strategic collaborations and partnerships to accelerate its research and development efforts and expand its market reach. Driven by a dedication to innovation, quality, and patient well-being, Glenmark Pharmaceuticals continues to make significant contributions to the global healthcare landscape.
Company Details
Key Leadership
Corporate Events
Latest News
GLENMARK Share Price: Frequently Asked Questions
What is the current share price of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd (GLENMARK) trades at ₹2233.90 on NSE and BSE. Market cap ₹64.82K (Cr). Educational data only.
What is the P/E ratio of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a P/E of 21.96x vs industry average 34.89x.
What is the Bull Run score for Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a Bull Run score of 70.7/100 based on 25+ financial parameters.
Does Glenmark Pharmaceuticals Ltd pay dividends?
Glenmark Pharmaceuticals Ltd has a dividend yield of 0.11%. Past dividends don't guarantee future payments.
What is the ROE of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has ROE of 30.49%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has debt-to-equity of 0.06.
Is Glenmark Pharmaceuticals Ltd a good investment?
Bull Run gives Glenmark Pharmaceuticals Ltd a score of 70.7/100. This is not investment advice — consult a SEBI-registered advisor.